Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLB1 | P16278 | 3/20 | 0.46 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.46 |
| ▸ | GBA1 | P04062 | 10/20 | 0.45 |
| ▸ | GUSB | P08236 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18853802 | 1.00 | GLB1 (0.46) | GLB1GBA2GBA1GUSBSMN1; SMN2 | |
| SCHEMBL670536 | 1.00 | GLB1 (0.46) | GLB1GBA2GBA1GUSBSMN1; SMN2 | |
| SCHEMBL20829025 | 0.98 | GBA1 (0.47) | GLB1GBA2GBA1GUSBLMNA | |
| SCHEMBL22764802 | 0.91 | CNR2 (0.39) | GLB1GBA2GBA1SMN1; SMN2LMNA | |
| SCHEMBL9623388 | 0.89 | LMNA (0.45) | GLB1GBA2GBA1GUSBSMN1; SMN2 | |
| SCHEMBL8749490 | 0.87 | GLB1 (0.44) | GLB1GBA2GBA1 | |
| SCHEMBL23964094 | 0.86 | CA1 (0.42) | GLB1GBA2GBA1CA1CA2 | |
| SCHEMBL8063152 | 0.79 | CA1 (0.48) | GLB1GBA2GBA1GUSBCA1 | |
| SCHEMBL22814864 | 0.79 | TBXA2R (0.37) | GLB1GBA2GBA1GUSBCA1 | |
| SCHEMBL19602220 | 0.79 | SMN1; SMN2 (0.44) | GLB1GBA2SMN1; SMN2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1333021-B1 | COMPOSITIONS CONTAINING DERIVATIVES OF JASMONIC ACID AND THEIR USE FOR STIMULATING SKIN PEELING | L'ORÉAL (FR) | 2017-10-04 | — | — | EP | disclosed |
| EP-1333021-B1 | COMPOSITIONS CONTAINING DERIVATIVES OF JASMONIC ACID AND THEIR USE FOR STIMULATING SKIN PEELING | L'ORÉAL (FR) | 2017-10-04 | — | — | EP | disclosed |
| EP-3168206-A1 | COMPOSITIONS COMPRISING DERIVATIVES OF JASMONIC ACID, AND USE OF SAID DERIVATIVES TO PROMOTE EXFOLIATION | L'OREAL (FR) | 2017-05-17 | — | — | EP | disclosed |
| EP-3168206-A1 | COMPOSITIONS COMPRISING DERIVATIVES OF JASMONIC ACID, AND USE OF SAID DERIVATIVES TO PROMOTE EXFOLIATION | L'OREAL (FR) | 2017-05-17 | — | — | EP | disclosed |
| US-8481594-B2 | Compositions comprising jasmonic acid derivatives and use of these derivatives | L'OREAL S. A. (FR) | 2013-07-09 | — | — | US | disclosed |
| US-8481594-B2 | Compositions comprising jasmonic acid derivatives and use of these derivatives | L'OREAL S. A. (FR) | 2013-07-09 | — | — | US | disclosed |
| US-20100179222-A1 | COMPOSITIONS COMPRISING JASMONIC ACID DERIVATIVES AND USE OF THESE DERIVATIVES | L'OREAL S.A. | 2010-07-15 | — | — | US | disclosed |
| US-20100179222-A1 | COMPOSITIONS COMPRISING JASMONIC ACID DERIVATIVES AND USE OF THESE DERIVATIVES | L'OREAL S.A. | 2010-07-15 | — | — | US | disclosed |
| US-20100069497-A1 | COMPOSITIONS COMPRISING JASMONIC ACID DERIVATIVES AND USE OF THESE DERIVATIVES | L'OREAL | 2010-03-18 | — | — | US | disclosed |
| US-20100069497-A1 | COMPOSITIONS COMPRISING JASMONIC ACID DERIVATIVES AND USE OF THESE DERIVATIVES | L'OREAL | 2010-03-18 | — | — | US | disclosed |
| EP-1333021-A2 | Compositions containing derivatives of jasmonic acid and their use for stimulating skin peeling | L'OREAL (FR) | 2003-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069497-A1 | COMPOSITIONS COMPRISING JASMONIC ACID DERIVATIVES AND USE OF THESE DERIVATIVES | CBR1, CBR3, DECR1 | GLB1 1183/4885GBA2 3560/4885GBA1 4160/4885 |
| US-20100179222-A1 | COMPOSITIONS COMPRISING JASMONIC ACID DERIVATIVES AND USE OF THESE DERIVATIVES | CBR1, CBR3, DECR1 | GLB1 1058/4885GBA2 3385/4885GBA1 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.